Title
Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition.

Permalink
https://escholarship.org/uc/item/4hr346ff

Journal
The Journal of experimental medicine, 176(6)

ISSN
0022-1007

Authors
Bluestone, JA
Jameson, S
Miller, S
et al.

Publication Date
1992-12-01

DOI
10.1084/jem.176.6.1757

Peer reviewed
Peptide-induced Conformational Changes in Class I Heavy Chains Alter Major Histocompatibility Complex Recognition

By Jeffrey A. Bluestone,* Stephen Jameson,† Stephen Miller,§ and Robert Dick II*

From the *Department of Pathology and the Committee on Immunology, Ben May Institute, University of Chicago, Chicago, Illinois 60637; the †Department of Immunology, University of Washington, Seattle, Washington 98195; and the §Department of Microbiology and Immunology, Northwestern University School of Medicine, Chicago, Illinois 60611

Summary
Small peptides, derived from endogenous proteins bind within the antigen binding groove created by the β-pleated sheets and α helices of the α1 and α2 domains of the class I molecule of the major histocompatibility complex (MHC). However, the precise role of peptide in class I MHC conformation remains unclear. Here, we have shown that, in at least some instances, changes induced in the MHC molecule by the binding of distinct peptides can be identified as specific alterations in serological epitopes expressed on the class I protein. The nature of specific peptides expressed by class I-bearing cells may, therefore, have a dramatic influence on T cell development, self-tolerance, and alloreactivity.

In recent years, tremendous progress has been made in elucidating the molecular aspects of MHC class I-peptide interaction. The structural analyses of crystallized HLA class I molecules have included A2, Aw68, and B27 (1–3). In all instances, small peptides have been observed within the cleft formed by the α helices and β-pleated sheet constituted by the α1 and α2 domains. Recent studies have shown that optimal peptide binding to the murine class I antigen, H-2Kb, occurs with small peptides (8–9) amino acids long, peptides containing a leucine at the COOH terminus, and amino acids with aromatic side chains (phenylalanine or tyrosine) at the 5th (8 mer) or 6th (9 mer) position (4–6). These amino acid residues provide the anchor points for the peptide in the cleft. The recent solution of the x-ray crystal structure of a single MHC class I molecule, H-2Kb, occupied by distinct peptides, suggested that these peptides may influence MHC class I conformation (7).

We, therefore, examined the role of peptide in MHC conformation using the mutant cell lines RMA-S and T2. These cell lines are class I-deficient somatic variants of RMA (mouse) and B-LCL721 (human) tumor cells due to defects in the transporter proteins, transporter associated with antigen processing (TAP), necessary for providing processed peptides for binding to the newly synthesized class I molecules (8–12). The addition of preprocessed antigenic peptides to these mutant cells results in stable assembly and cell surface expression of class I predominantly bound to the added peptide.

In the present experiments, we studied the effects of specific peptides on class I recognition of H-2Kb-specific alloantibodies. The peptide transporter mutants, RMA-S and T2-Kb/Dd, were pulsed with various Kb binding peptides. Class I molecules bound by the different peptides were distinguishable by mAb binding. These results suggest that, in at least some instances, MHC conformation as detected by serological epitopes may depend on the peptide bound to the class I molecule.

Materials and Methods

Tumors. The Rauscher virus-transformed lymphoma cells, RMA and RMA-S (13), were a gift from Dr. K. Karre (Karolinska Institute, Stockholm, Sweden). The human T cell lymphomas, C1R and B-LCL721.174 × CEM, (T2 [14]), were the kind gift of Dr. P. Cresswell (Yale University, New Haven, CT). The T2 cells were transfected with a chimeric MHC class I gene, Kβ/Dd (i.e., exons 2 and 3 encoding the α1 and α2 domains of Kβ ligated to exon 4 encoding the α3 domain of Dd; kindly provided by Dr. T. Potter (National Jewish Hospital, Denver, CO) by electroporation.

Peptide Preparation and Binding Assays. The majority of the peptides were prepared by solid-phase techniques using the F-moc method, or by the University of Chicago Peptide Synthesis Laboratory by the T-boc method, and analyzed by HPLC for purity. Amino acid analyses were performed to assure appropriate amino acid composition. The peptides used in the present studies included: OVA 257-264 (SIINFEKL [15]); influenza nucleoprotein 1968 (FLU NP) 345-360 (SFIRGTKVSPRGKLST [16]); vesicular stomatitis virus nucleoprotein (VSV NP) 52-59 (RGYVYQGL [17]); and Sendai virus nucleoprotein 322-330 (APGNYPAL; SV8 NP) or 321-
Results and Discussion

To assess class I conformational features, the binding of a panel of mAbs specific for H-2K\(^{b}\) was examined on wild-type, RMA, and mutant, RMA-S tumor lines in the absence or presence of distinct exogenous peptides. As seen in Fig. 1, four anti-H-2K\(^{b}\) mAbs reacted with the wild-type RMA cells whereas RMA-S cells, when incubated at 37°C, expressed little H-2K\(^{b}\). In contrast, overnight incubation of RMA-S at room temperature upregulated K\(^{b}\) expression (right). However, examination of the relative binding of the different mAbs to RMA-S RT revealed that 100-30 bound proportionally greater than 5F1-2-14 or Y-3, a serological pattern different from that seen on RMA.

The serological profile of K\(^{b}\) molecules on RMA-S pulsed with exogenous peptides was also significantly different than RMA. The serology of RMA-S cells pulsed with SV8 NP, SV9 NP, and FLU-NP peptides was similar to the RMA-S RT cells as 5F1-2-14 bound relatively poorly, if at all (SV9 NP), to these cells, and 100-30 reacted strongly. In contrast, K\(^{b}\) molecules expressed by RMA-S cells incubated with the OVA peptide or VSV NP peptide reacted strongly with the 5F1-2-14 mAb. In addition, there was virtually no binding of the 100-30 mAb to OVA-pulsed RMA-S cells and weak binding to VSV NP-pulsed RMA-S. The relative differences in the K\(^{b}\) reactivity were not due to antibody titer or isotype, as shown in Fig. 2. All of the antibodies bound at different saturating levels on each cell type. For instance, plateau binding of 5F1-2-14 occurred with a mean fluorescence (MF) of 325 on OVA-pulsed RMA-S cells, but only MF 50 on SV8 NP-pulsed RMA-S. In contrast, 100-30 bound with a MF of 125 and 15 on SV8 NP- and OVA-pulsed RMA-S cells, respectively. The differences in maximal antibody binding, combined with the dramatically different slopes of the titration curves, suggested that the same mAb has different affinities for the K\(^{b}\) molecule associated with different peptides. It is interesting that another mAb, AF6-88.5, whose K\(^{b}\) binding was previously reported to be murine β\(_2\)M dependent (25), and did not react with human β\(_2\)M-associated human C1R-K\(^{b}\) cells (data not shown), also demonstrated different binding activity on K\(^{b}\) molecules loaded with the different peptides. RMA-S cells pulsed with OVA, VSV NP, and SV9 NP bound AF6-88.5 well, whereas RMA-S RT, RMA-S plus SV8 NP, and RMA-S FLU-NP (data not shown) bound it poorly. Therefore, it is likely that the AF6-88.5 binding is dependent on both murine β\(_2\)M association and peptide-induced class I conformation, perhaps at the site where β\(_2\)M interacts with the α\(_3\) domain of K\(^{b}\) (26).

To determine the absolute binding of the K\(^{b}\)-specific mAbs, T2 cells were transfected with a chimeric K\(^{b}\)/D\(^{d}\) construct encoding the α\(_1\) and α\(_2\) domains of K\(^{b}\) and the α\(_3\) domain of D\(^{d}\). This chimeric MHC molecule can be identified by an α\(_3\)-specific mAb, 34-2-12, that is not influenced by peptide binding. As seen in Fig. 3 a, the pattern of mAb binding varied significantly among the peptide-pulsed T2-K\(^{b}\)/D\(^{d}\) tumor lines. Anti-H-2D\(^{d}\) binding increased equivalently on transfectants pulsed with SV9 and OVA peptides (dashed lines). Furthermore, there was a dramatic difference in the reactivity of 5F1 (solid lines) between the two peptide-pulsed cell populations. Similar dramatic differences were observed when K\(^{b}\)-specific mAb reactivity was normalized to the α\(_3\)-specific mAb staining (Fig. 3 b). Two conclusions can be drawn from this data. First, the staining of peptide-pulsed K\(^{b}\)/D\(^{d}\)-transfected T2 cells was remarkably similar to the RMA-S cells cultured...
Figure 3. Serological analyses of peptide-pulsed T2-Kb/Dd cells. (a) FCM analyses were performed as in Fig. 2 on T2-Kb/Dd cells pulsed with individual peptides overnight. Data is depicted as histograms of 10,000 cells. Background staining with FITC-coupled anti-mouse Ig is shown (spread dots). Cells were stained with 5F1-2-14 (solid lines), 100-30 (dotted lines), and 34-2-12 (anti-Dd, dashed lines). (b) Kb/Dd staining ratios were determined by dividing the maximal mean log fluorescence of the individual anti-Kb mAbs by the maximal mean log fluorescence of the α3-specific, anti-Dd mAb, 34-2-12. In this experiment, 34-2-12 stained unpulsed T2-Kb with a mean log fluorescence of 500, whereas the mean fluorescence of peptide-pulsed Kb ranged from 1,300 to 1,500.

with the different peptides. For instance, the absolute binding of 5F1-2-14 was much more efficient on OVA-pulsed cells than on SV9 NP cells. In contrast, 100-30 did not bind OVA-pulsed cells at all, but bound very well to SV9 NP-pulsed cells. In fact, these serological alterations were observed in as little as 1-h incubation with peptide (data not shown). Second, recent studies have shown that the nonamer peptide of the Sendai NP binds 1,000-fold better than the octamer. Yet, with the exception of 5F1-2-14 binding, which was weak on SV8 NP-pulsed RMA-S but nonexistent on SV9 NP-pulsed cells, the mAb binding pattern observed with SV9 and SV8...
NP was similar, whereas mAb-binding to SV8 NP- and OVApulsed cells was quite dissimilar. Thus, the differences in serology of the K\textsuperscript{b} molecule loaded with different peptides did not correlate with peptide length or affinity.

A dose titration of OVA peptide on T2-K\textsuperscript{b}/D\textsuperscript{d} showed that overnight incubation with as little as $10^{-3}$–$10^{-4}$ μg/ml of OVA peptide resulted in a diminution of 100–30 mAb binding and a concomitant increase in 5F1-2-14 binding (Fig. 4 a). A more detailed analysis of the influence of the OVA peptide on K\textsuperscript{b} serology was performed using OVA peptides in which individual amino acids were substituted with alanine residues. As illustrated in Fig. 4 b, OVA peptides containing substituted alanines at positions 261 or 264 did not increase K\textsuperscript{b} expression. In previous studies by Falk et al. (4, 27), residues 5 (amino acid 261) and 8 (amino acid 264) were shown to be critical residues for peptide binding to K\textsuperscript{b}. Thus, it is not surprising that these alanine substitutions affected MHC binding. In contrast, significant increases in H-2K\textsuperscript{b} expression was observed with all other alanine-substituted peptides. The reactivity of four different mAbs on OVA-pulsed RMA-S cells was not significantly effected by several individual alanine substitutions including: OVA peptide-serine 257 --* alanine 257 (OVA-S257A), OVA-I258A, OVA-N260A, or OVA-E262A. However, substitution of the isoleucine 259 with an alanine resulted in diminished AF6.88-5 peptide-serine 257 --* alanine 257 (OVA-S257A), OVA-I258A, OVA-N260A, or OVA-E262A. However, substitution of the isoleucine 259 with an alanine resulted in diminished AF6.88-5

The authors wish to thank Drs. Terry Potter and Peter Cresswell for providing most valuable reagents for these studies. In addition, we would like to thank Mr. David Kennedy for flow cytometry, and Drs. Andrea Sant, Michael Bevan, and Jim Miller for helpful discussions and review of the manuscript.

This work was supported by U.S. Public Health Service grants P01 AI-29531 and P30 CA-14599. J. A. Bluestone is a recipient of an American Cancer Society Faculty Research Award.

Address correspondence to Dr. Jeffrey A. Bluestone, University of Chicago, MC1089, 5841 S. Maryland Avenue, Chicago, IL 60637.

Received for publication 20 July 1992 and in revised form 30 September 1992.
References

1. Saper, M.A., P.J. Bjorkman, and D.C. Wiley. 1991. Refined structure of the human histocompatibility antigen, HLA-A2 at 2.6Å resolution. J. Mol. Biol. 219:277.

2. Madden, D.R., J.C. Gorga, J.L. Strominger, and D.C. Wiley. 1991. The structure of HLA-B27 reveals nonomert self-peptides bound in an extended conformation. Nature (Lond.). 353:321.

3. Garrett, T.P., M.A. Saper, P.J. Bjorkman, J.L. Strominger, and D.C. Wiley. 1989. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature (Lond.). 342:692.

4. Falk, K., O. Rötzschke, S. Stevanović, G. Jung, and H.G. Ram- mensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.). 351:290.

5. Shibata, K., M. Imarai, G.M. van Bleek, S. Joyce, and S.G Nathenson. 1992. Vesicular stomatitis virus antigenic octapeptide N52-59 is anchored into the groove of the H-2Kb molecule by the side chains of three amino acids and the main-chain atoms of the amino terminus. Proc. Natl. Acad. Sci. USA. 89:3135.

6. van Bleek, G.M., and S.G. Nathenson. 1991. The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self-peptides. Proc. Natl. Acad. Sci. USA. 88:11032.

7. Fremont, D.H., M. Matsumura, E.A. Stura, P.A. Peterson, and I.A. Wilson. 1992. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science (Wash. DC). 257:919.

8. Attaya, M., S. Jameson, C.K. Martinez, E. Hermel, C. Aïdritch, J. Forman, K.F. Lindahl, M.J. Bevan, and J.J. Monaco. 1992. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature (Lond.). 355:647.

9. Powis, S.J., A.R. Townsend, E.V. Deverson, J. Bastin, G.W. Butcher, and J.C. Howard. 1991. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature (Lond.). 354:528.

10. Spies, T., V. Cerundolo, M. Colonna, P. Cresswell, A. Tow- nsend, and R. DeMars. 1992. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature (Lond.). 355:644.

11. Monaco, J.J. 1992. A molecular model of MHC class I restricted antigen processing. Immunol. Today. 13:173.

12. Wei, M.L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature (Lond.). 356:443.

13. Ljunggren, H.G., S. Piabò, M. Cochet, G. Kling, P. Kourtakis, and K. Karre. 1989. Molecular analysis of H-2-deficient lymphoma lines. Distinct defects in biosynthesis and association of MHC class I heavy chains and beta 2-microglobulin observed in cells with increased sensitivity to NK cell lysis. J. Immunol. 142:2911.

14. Salter, R.D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO (Eur. Mol. Biol. Organ.) J. 5:943.

15. Carbone, F.R., and M.J. Bevan. 1989. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J. Exp. Med. 169:603.

16. Townsend, A.C. Ohlén, J. Bastin, H.G. Ljunggren, L. Foster, and K. Karre. 1989. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (Lond.). 340:443.

17. van Bleek, G.M., and S.G. Nathenson. 1990. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature (Lond.). 348:213.

18. Schumacher, T.N., M.T. Heemels, J.J. Neefjes, W.M. Kast, C.J. Mielief, and H.L. Ploegh. 1990. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell. 62:563.

19. Sherman, L.A., and C.P. Randolph. 1981. Monoclonal anti- H-2Kb antibodies detect serological differences between H-2Kb mutants. Immunogenetics. 12:183.

20. Geier, S.S., R.A. Zeff, D.M. McGovern, T.V. Rajan, and S.G. Nathenson. 1986. An approach to the study of structure-function relationships of MHC class I molecules: isolation and serologic characterization of H-2Kb somatic cell variants. J. Immunol. 137:1239.

21. Loken, M.R., and A.M. Stall. 1982. Flow cytometry as an analytical and preparative tool in immunology. J. Immunol. Methods. 50:R85.

22. Lemke, H., G.J. Hammerling, and U. Hammerling. 1979. Fine specificity analysis with monoclonal antibodies of antigens controlled by the major histocompatibility complex and by the Qa/TL region in mice. Immunol. Rev. 47:175.

23. Jones, B., and C.A. Janeway, Jr. 1981. Cooperative interaction of B lymphocytes with antigen-specific helper T lymphocytes is MHC restricted. Nature (Lond.). 292:547.

24. Ozato, K., N.M. Mayer, and D.H. Sachs. 1982. Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation (Baltimore). 34:113.

25. Rock, K.L., C. Gramm, and B. Benacerraf. 1991. Low temperature and peptides favor the formation of class I heterodimers on RMA-S cells at the cell surface. Proc. Natl. Acad. Sci. USA. 88:4200.

26. Bluestone, J.A., and T. Potter. 1989. T cell clones and monoclonal antibodies: immunologic probes of major histocompatibility complex class I molecules. Chem. Immunol. 46:23.

27. Falk, K., O. Rötzschke, K. Deres, J. Metzger, G. Jung, and H. G. Rammensee. 1991. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174:425.

28. Ajitkumar, P.S., S.S. Geier, K.V. Kesari, F. Borriello, M. Nakagawa, J.A. Bluestone, M.A. Saper, D.C. Wiley, and S.G. Nathenson. 1988. Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor. Cell. 54:47.

29. Aosai, F., C. Ohlen, H.G. Ljunggren, P. Höglund, L. Franksson, H. Ploegh, A. Townsend, K. Karre, and H.J. Stauss. 1991. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur. J. Immunol. 21:2677.

30. Rötzschke, O., K. Falk, S. Faath, and H.G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174:1059.

31. Guimezesas, A., T.N.M. Schumacher, H.L. Ploegh, and A.-M. Schmitt-Verhulst. 1992. A viral peptide can mimic an endogenous peptide for all...